DXR
DAXOR CORP$9.21 −0.04 (−0.43%)
Oct 26 4:00 PM ET · prev $9.25
Market cap
$54.9M
Micro cap
Median target
$20.00
+117% · range $18.00–22.00
1 year
−19.6%
from $11.45 · Oct 27
30 days
−18.9%
from $11.35
52-week range
$8.87–14.75
−38% from high · low Apr 7
Avg volume 20D
13.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$19.0K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- B Mar 20 1 insider buy $0.00
- B Mar 31 1 insider buy $9.9K at $9.90
- B Apr 8 1 insider buy $9.1K at $9.07
- X Jul 31 Short interest falls 76.4% to 348
- X Aug 31 Short interest jumps 93.5% to 592
- X Sep 15 Short interest jumps 293.8% to 2.3K
- X Sep 30 Short interest jumps 198.5% to 7.0K
Signal stack
Where each data set points today.
- InsidersBULLISH
3 insiders bought $19.0K at an average $9.49. No open-market sales.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 0 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.110 → −$0.080 over 90 days. 1 up, 0 down in 30 days.
- TrendDOWNTREND
13% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | $275.4K |
| JPMORGAN CHASE & CO | DOUBLED | $61.00 |
| JPMORGAN CHASE & CO | NEAR_EXIT | $10.00 |
| JPMORGAN CHASE & CO | ADD | $74.00 |
| UBS Group AG | NEAR_EXIT | $2.6K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $213.9K |
| UBS Group AG | DOUBLED | $20.0K |
| MORGAN STANLEY | DOUBLED | $681.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Mar 202512-month targets · 2 analysts
$9.21 $18.00 $20.00 $22.00
Price is below the lowest target. Median implies +117%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Mar 17, 2025 | Ascendiant Capital MAINTAIN | Buy |
| Sep 9, 2024 | Ascendiant Capital MAINTAIN | Buy |
| Jul 29, 2019 | Maxim Group INITIATE | Buy |
| May 16, 2019 | Ascendiant Capital INITIATE | Buy |
Insider ledger
Form 4$19.0K
bought · 3 insiders
$0
sold · 0 insiders
−2.9%
vs their $9.49 cost
| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 28, 2026 | Jefferies John Chief Medical Officer | AWARD | 2,451 sh |
| Jun 23, 2026 | DesRosiers Caleb Director | AWARD | 2,500 sh |
| Jun 23, 2026 | Feuer Edward Director | AWARD | 2,500 sh |
| Jun 23, 2026 | Cremisi Henry D. Director | AWARD | 2,500 sh |
| Jun 23, 2026 | Goudie Joy S. Director | AWARD | 2,500 sh |
| Jun 23, 2026 | Feldschuh Jonathan Adam Chief Scientific Officer | AWARD | 25,000 sh |
| Jun 23, 2026 | Feldschuh Michael Richard Chief Executive Officer | AWARD | 30,000 sh |
| Jun 23, 2026 | Michel Robert J Chief Financial Officer | AWARD | 12,000 sh |
Earnings setup
Estimates−$0.08
EPS estimate, this quarter
+27%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
−$0.11090d
−$0.11060d
−$0.11030d
−$0.1107d
−$0.080Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.08 | -$0.08–-$0.08 | +27.3% | $1.8M |
| Next Q | -$0.06 | -$0.06–-$0.06 | -100.0% | $2.0M |
| Current FY | -$0.21 | -$0.21–-$0.21 | +0.0% | $9.3M |
| Next FY | -$0.03 | -$0.03–-$0.03 | +0.0% | $16.4M |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines
Aug 28, 2026 Insider
Jefferies John was granted 2,451 shares
Chief Medical Officer
Jun 30, 2026 Inst.
SUSQUEHANNA INTERNATIONAL GROUP, LLP — ADD
27,131 shares ($275.4K)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — DOUBLED
6 shares ($61.00)
Jun 23, 2026 Insider
DesRosiers Caleb was granted 2,500 shares
Director
Jun 23, 2026 Insider
Feuer Edward was granted 2,500 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Press release
Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of…
Sep 8, 2026
Press release
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology…
Jul 29, 2026
Press release
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model
Jul 7, 2026
Press release
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy
Apr 28, 2026
Press release
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today…